

Novo Nordisk shares drop amid US pricing concerns

August 5 2016

Shares in the world's largest maker of diabetes treatments, Novo Nordisk, fell more than eight percent on Friday after the company said prices were under pressure in the United States and lowered its growth forecast.

The stock was 8.7 percent lower in early afternoon trading on the Copenhagen exchange, where the main index was 3.5 percent lower, even as the group posted a 19 percent rise in quarterly earnings.

In the United States, negotiations with the firms that manage prescription drug services between health insurers and insured patients for 2017 "have reflected an intensifying price competition," chief executive Lars Rebien Sorensen said in a statement.

"In spite of this, we see significant growth opportunities based on our strong diabetes care portfolio," he added.

Although price pressure in the United States "may have been expected... the level is probably a tad higher than what the market had expected," Jyske Bank trader Kim Sejdelin Christensen told Danish news agency Ritzau.

Sales were expected to grow by between five and seven percent in local currencies this year, rather than a previous estimate of five to nine percent, the company said.

Operating profit was expected to grow by between five and eight percent in local currencies, down from an earlier prediction of five to nine percent.

Net profit in the second quarter rose 19 percent to 9.97 billion kroner (1.34 billion euros, \$1.49 billion), compared to a Bloomberg analyst estimate average of 9.91 billion kroner, as revenue edged up one percent to 27.46 billion kroner.

Sales growth of Victoza, which controls blood sugar levels by mimicking an intestinal hormone called GLP-1, and once-daily insulin Tresiba continued to be strong in the first half of the year, Sorensen said.

The number of adults estimated to be living with diabetes nearly quadrupled between 1980 and 2014 to 422 million, according to the World Health Organization.

Novo Nordisk holds a 46 percent share of the international insulin market.

© 2016 AFP

Citation: Novo Nordisk shares drop amid US pricing concerns (2016, August 5) retrieved 3 May 2024 from <https://medicalxpress.com/news/2016-08-novo-nordisk-growth-profit.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.